BioLife Solutions, Inc. (BLFS)
NasdaqCM
Price as at 30 Sept 2026, 16:33 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
BioLife Solutions, Inc. trades at $39.20. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Israel Englander, MILLENNIUM MANAGEMENT LLC$17.67M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$4.46M · 0.0% of book
- Diamond Hill, Diamond Hill Capital Management, LLC (Investment Advisor)$4.35M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$988.9K · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$669.1K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in BLFS
Trades in BLFS disclosed by members of Congress and executive-branch officials, latest first:
- Christopher L. Jacobs · HouseSell · $1,001 - $15,000 · traded 12 Dec 2022 · disclosed 20 Jan 2023
- Christopher L. Jacobs · HouseBuy · $1,001 - $15,000 · traded 8 Nov 2022 · disclosed 12 Dec 2022
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own BLFS?
7 of the institutions we track reported a position in BLFS in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its BLFS data?
Fundamentals for BLFS come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:33 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for BLFS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.